文献速递心脑血管急症

荷兰新发非瓣膜性心房颤动患者特征、抗凝治疗与预后的时间趋势

Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands.
PubMed 文献 · JAMA Netw Open · 2023-04-03
一句话结论荷兰2014—2018年新发非瓣膜性房颤患者基线特征相似,口服抗凝药使用增加且DOAC逐渐替代VKA,1年缺血性卒中与major bleeding累积发生率均下降。

该回顾性队列研究利用荷兰统计局数据,纳入2014—2018年住院期间首次诊断的非瓣膜性房颤患者301 301例(平均年龄74.2岁,56.3%为男性),按诊断日历年分为5个队列,随访1年。结果显示各队列基线特征大致相同(平均CHA2DS2-VASc评分2.9),口服抗凝药覆盖天数中位比例从56.99%升至75.62%,DOAC在口服抗凝药使用者中从5102例(13.5%)增至32 314例(72.0%),逐渐替代VKA。1年缺血性卒中累积发生率从1.63%降至1.39%,major bleeding从2.50%降至2.07%,校正基线特征并排除既往长期抗凝者后关联一致。作者认为合并症负担、抗凝药潜在使用不足及特定亚组仍是未来改进方向。

要点

  • 2014—2018年荷兰新发非瓣膜性房颤患者301 301例,平均年龄74.2岁,56.3%为男性,平均CHA2DS2-VASc评分2.9。
  • 1年内口服抗凝药覆盖天数中位比例从56.99%升至75.62%,DOAC在口服抗凝药使用者中从5102例(13.5%)增至32 314例(72.0%)。
  • 1年缺血性卒中累积发生率从1.63%(95%CI 1.52%-1.73%)降至1.39%(95%CI 1.30%-1.48%)。
  • 1年major bleeding累积发生率从2.50%(95%CI 2.37%-2.63%)降至2.07%(95%CI 1.96%-2.19%)。
  • 校正基线特征并排除既往长期抗凝者后,上述下降关联一致。

适用人群与场景

  • 2014—2018年荷兰住院期间首次诊断的非瓣膜性房颤患者,共301 301例,平均(SD)年龄74.2(11.9)岁,169 748例(56.3%)为男性。
  • 按诊断日历年分为5个队列,从住院 admission 起随访1年或至死亡。

诊断标准与关键阈值

  • 非瓣膜性房颤诊断依据住院期间首次识别,具体诊断标准原文未报告。
  • CHA2DS2-VASc评分组成:充血性心力衰竭、高血压、年龄≥75岁(双倍)、糖尿病、卒中(双倍)、血管疾病、年龄65—74岁、性别类别(女性);平均(SD)评分2.9(1.7)。

处置流程与药物剂量

  • 口服抗凝药包括维生素K拮抗剂(VKA)或DOAC;1年内口服抗凝药覆盖天数中位(IQR)比例从2014年56.99%(0%-86.30%)升至2018年75.62%(0%-94.52%)。
  • DOAC在口服抗凝药使用者中从5102例(13.5%)增至32 314例(72.0%),逐渐替代VKA成为口服抗凝药首选。

研究设计与关键结果

  • 研究类型:回顾性队列研究,数据来自荷兰统计局(Statistics Netherlands),纳入2014—2018年住院期间首次诊断的非瓣膜性房颤患者301 301例,按诊断日历年分为5个队列,随访1年。
  • 主要终点:1年缺血性卒中累积发生率从1.63%(95%CI 1.52%-1.73%)降至1.39%(95%CI 1.30%-1.48%);1年major bleeding累积发生率从2.50%(95%CI 2.37%-2.63%)降至2.07%(95%CI 1.96%-2.19%)。
  • 校正基线患者特征并排除既往长期抗凝者后,上述下降关联一致。
  • 基线特征各队列大致相同,平均(SD)CHA2DS2-VASc评分2.9(1.7)。
  • 口服抗凝药覆盖天数中位(IQR)比例从56.99%(0%-86.30%)升至75.62%(0%-94.52%);DOAC在口服抗凝药使用者中从5102例(13.5%)增至32 314例(72.0%)。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该研究提示2014—2018年荷兰新发非瓣膜性房颤患者口服抗凝药使用增加、DOAC逐渐替代VKA,同时1年缺血性卒中与major bleeding累积发生率下降。
  • 作者认为合并症负担、抗凝药潜在使用不足及特定非瓣膜性房颤患者亚组仍是未来研究和进一步改进的方向。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: The temporal trend in adverse events regarding stroke prevention for nonvalvular atrial fibrillation (NVAF) in the direct oral anticoagulant (DOAC) era was rarely investigated comprehensively, especially taking into account potential changes in patient characteristics and anticoagulation treatment.

OBJECTIVE: To investigate time trends in patient characteristics, anticoagulation treatment, and prognosis of patients with incident NVAF in the Netherlands.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study assessed patients with incident NVAF initially recognized within a hospitalization between 2014 and 2018, using data from Statistics Netherlands. Participants were followed-up for 1 year from the hospital admission at which the incident NVAF diagnosis was made or until death, whichever occurred first. Data were analyzed from January 15, 2021, to March 8, 2023.

EXPOSURE: Calendar year of the incident NVAF diagnosis, according to which the participants were categorized into 5 cohorts.

MAIN OUTCOMES AND MEASURES: Outcomes of interest were baseline patient characteristics, anticoagulation treatment, and occurrence of ischemic stroke or major bleeding within the 1-year follow-up after incident NVAF.

RESULTS: Between 2014 and 2018, 301 301 patients (mean [SD] age, 74.2 [11.9] years; 169 748 [56.3%] male patients) experienced incident NVAF in the Netherlands, each of whom was categorized into 1 of 5 cohorts by calendar year. Baseline patient characteristics were broadly the same between cohorts with a mean (SD) CHA2DS2-VASc (congestive heart failure, hypertension, age ≥75 years [doubled], diabetes, stroke [doubled], vascular disease, age 65 to 74 years, and sex category [female]) score of 2.9 (1.7). The median (IQR) proportion of days covered by OACs (ie, vitamin K antagonists or DOACs) within the 1-year follow-up increased from 56.99% (0%-86.30%) to 75.62% (0%-94.52%), and DOACs increased from 5102 patients (13.5%) to 32 314 patients (72.0%) among those who received OACs, gradually replacing VKAs as the first choice of OACs. Over the course of the study, there were statistically significant decreases in the 1-year cumulative incidence of ischemic stroke (from 1.63% [95% CI, 1.52%-1.73%] to 1.39% [95% CI, 1.30%-1.48%) and major bleeding (from 2.50% [95% CI, 2.37%-2.63%] to 2.07% [95% CI, 1.96%-2.19%]), and the association was consistent after adjusting for baseline patient characteristics and excluding those with preexisting chronic anticoagulation.

CONCLUSIONS AND RELEVANCE: This cohort study of patients with incident NVAF diagnosed between 2014 and 2018 in the Netherlands found similar baseline characteristics, increased OAC use with DOACs being favored over time, and improved 1-year prognosis. Comorbidity burden, potential underuse of anticoagulation medications, and specific subgroups of patients with NVAF remain directions for future investigations and further improvement.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Chen Q, Toorop MMA, Tops LF, et al. Time Trends in Patient Characteristics, Anticoagulation Treatment, and Prognosis of Incident Nonvalvular Atrial Fibrillation in the Netherlands. JAMA Netw Open. 2023. PMID: 37097630. doi:10.1001/jamanetworkopen.2023.9973

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。